Jaguar Health, Inc.

Jaguar Health, Inc. develops and commercializes plant-based prescription and non-prescription products for human and animal health, with a portfolio centered on crofelemer-based therapies and related botanical medicines. The company also uses licensing and partnership structures to extend its products and pipeline, including Mytesi, Canalevia-CA1, Gelclair, and early-stage botanical drug candidates through its Magdalena joint venture.

−382,2 %

99,2 %

−465,4 %

−1,5 %

0.50

0.29

— Jaguar Health, Inc.
	%
Human prescription products	55% Includes Mytesi, crofelemer-based follow-on indications, and licensed human therapies such as Gelclair.
Animal health products	25% Includes Canalevia-CA1 and Neonorm products sold for companion animals and livestock.
License and royalty revenue	15% Includes revenue from licensing arrangements such as the Gen territory agreement and other partner monetization.
Early-stage pipeline and collaborations	5% Includes Magdalena and other botanical drug development efforts that are not yet commercial revenue drivers.

Jaguar sells mainly to distributors, wholesalers, and specialty pharmacies, which then supply patients, veterinarians,...

Distributors and wholesalersprimary
Buy Mytesi, Canalevia-CA1, and Neonorm products for onward sale into pharmacy and veterinary channels.
Specialty pharmaciessecondary
Dispense Mytesi to patients under prescription and support access for niche human indications.
Animal health channel partnerssecondary
Purchase animal products for resale to veterinarians, livestock operators, and end customers.
Licensees and collaboration partnersprimary
Monetize territory rights or development assets and provide upfront or ongoing license revenue.
Future pharmaceutical partnersemerging
Potential partners for crofelemer follow-on indications and Magdalena pipeline assets.

Jaguar is headquartered in the United States and generates most of its operating activity there, including product...

•United States is the core operating and commercialization market
•U.S. FDA approval and review timing are critical to pipeline value
•International licensing expands reach without heavy foreign infrastructure
•U.K.-based Venture Life is a source of licensed product rights
•Global rights to crofelemer support future partnership optionality

Jaguar is focused on extending the commercial life of crofelemer while building new plant-based drug opportunities...

Advance crofelemer follow-on indicationsmedium-term

New indications could broaden the commercial opportunity beyond current products and create partnership value.

Monetize through partnerships and licensesshort-term

Upfront fees, territory licenses, and collaboration economics can fund operations without full internal commercialization costs.

Support existing product commercializationshort-term

Current product sales provide operating traction and validate the botanical drug platform.

Preserve liquidity and capital accessshort-term

The company has recurring losses and needs external funding to continue development and commercialization.

Jaguar remains a development-stage pharmaceutical company with recurring losses, limited cash, and dependence on...

high

Liquidity shortfall and financing dependence

The company has recurring operating losses and may not fund its plan from existing cash.

Scope: Operating plan, development spend, commercialization
Materiality: high

high

FDA review and approval delays

Regulatory disruptions can slow submissions, meetings, inspections, and approvals.

Scope: Pipeline timing and product launches
Materiality: high

high

Minimum royalty payment obligations

Royalty interests require payments even if product sales are insufficient.

Scope: Cash flow and debt-like burden
Materiality: high

high

Clinical development failure

Pipeline assets depend on positive human trial and proof-of-concept results.

Scope: Crofelemer follow-on indications, Magdalena candidates
Materiality: high

medium

Cost inflation and margin pressure

Higher raw material, labor, and distribution costs can compress gross margins.

Scope: Product revenue profitability
Materiality: medium

Revenue recognition for product and license revenue

Quarterly revenue mix can be volatile

Sales returns reserve

Can reduce reported net revenue

Fair value measurement of financial instruments

Can create non-cash earnings volatility

Debt extinguishment accounting

Affects operating loss comparability

Royalty obligations and minimum payments

Important for liquidity analysis and covenant-like pressure

Jaguar Health, Inc.

Liquidity shortfall and financing dependence

FDA review and approval delays

Minimum royalty payment obligations

Clinical development failure

Cost inflation and margin pressure

Merck & Co., Inc.

Pacira BioSciences, Inc.

Jazz Pharmaceuticals plc

BIO-PATH HOLDINGS, INC.

GENELUX Corp

electroCore, Inc.